Seeking to rapidly identify new treatments

£10m in funding

15 clinical trials

30 organisations involved

3 continents

Why drug repurposing?

Compared with developing novel therapeutics and vaccines, re-purposing of existing medicines or those in late stage trials offers the fastest route to the patient.

What are the benefits?

• reduced risk of failure as safety and dosing profile typically well established
• product and supply chains already available
• patients ready to commence trial enrolment

LifeArc considered repurposing drugs as likely to be most impactful in this global pandemic, 2020/21.

LifeArc repurposing time frames for proof of safety and efficacy in COVID patients:

Total time frame - up to one year

Identify existing compounds, design trial and select proposal

Commence trial and patient enrolment

Evaluate outcome and gain approvals

Standard novel drug development time frame:

Total time frame - average 12 years

4-5 years Discovery and development

2-3 years Preclinical (including toxicology)

7 years Clinical trials

1-2 years marketing approval